Recorded Presentation from the NCCN Pharmacy Updates: Emerging Strategies for Pediatric Acute Lymphoblastic Leukemia Management
Pediatric ALL is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment of this disease will help clinicians play an important role in providing medication-related recommendations, supportive care, and patient counseling which can improve the outcomes and the quality of patient care.
NCCN Pharmacy Updates: Emerging Strategies for Pediatric Acute Lymphoblastic Leukemia Management
Pediatric ALL is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment of this disease will help clinicians play an important role in providing medication-related recommendations, supportive care, and patient counseling which can improve the outcomes and the quality of patient care.
Management of Recurrent Acute Lymphoblastic Leukemia with T-Cell Engagement: CAR T, BiTEs, and Beyond

Recent advances in cancer immunotherapy have led to novel treatment options in the setting of relapsed or refractory acute lymphoblastic leukemia (R/R ALL).

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Pediatric Acute Lymphoblastic Leukemia (ALL)
Informing clinicians about emerging strategies for pediatric ALL management will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize short- and long-term treatment-related toxicities.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Pediatric Acute Lymphoblastic Leukemia (ALL)

Emerging Strategies for Pediatric ALL Management

NCCN Guidelines® Insights - Acute Lymphoblastic Leukemia, Version 1.2019

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy.

Recorded Presentations from the NCCN 2018 Congress Webinar Series: Acute Leukemia

During 2017, the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010.

Recorded Presentation from the NCCN 2018 Congress Webinar Series: Acute Leukemia - Monitoring Minimal Residual Disease in Leukemia and Impact on Treatment

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

Recorded Presentation from the NCCN 2018 Congress Webinar Series: Acute Leukemia - Refractory Acute Lymphoblastic Leukemia Management: New Insights

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

Recorded Presentation from the NCCN 2018 Congress Webinar Series: Acute Leukemia - Impact of Changing Molecular Landscape on Leukemia Management

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

Pages

Subscribe to RSS - Acute Lymphoblastic Leukemia